LIVN vs. SOLV, PEN, STVN, IRTC, GKOS, BLCO, SLNO, TMDX, NVST, and WRBY
Should you be buying LivaNova stock or one of its competitors? The main competitors of LivaNova include Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), iRhythm Technologies (IRTC), Glaukos (GKOS), Bausch + Lomb (BLCO), Soleno Therapeutics (SLNO), TransMedics Group (TMDX), Envista (NVST), and Warby Parker (WRBY). These companies are all part of the "medical equipment" industry.
LivaNova vs. Its Competitors
Solventum (NYSE:SOLV) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.
In the previous week, Solventum had 10 more articles in the media than LivaNova. MarketBeat recorded 22 mentions for Solventum and 12 mentions for LivaNova. LivaNova's average media sentiment score of 1.37 beat Solventum's score of 0.88 indicating that LivaNova is being referred to more favorably in the news media.
Solventum has a net margin of 4.52% compared to LivaNova's net margin of -16.13%. Solventum's return on equity of 29.93% beat LivaNova's return on equity.
Solventum presently has a consensus target price of $85.44, indicating a potential upside of 16.75%. LivaNova has a consensus target price of $59.71, indicating a potential upside of 7.73%. Given Solventum's higher possible upside, equities analysts clearly believe Solventum is more favorable than LivaNova.
97.6% of LivaNova shares are held by institutional investors. 0.1% of Solventum shares are held by insiders. Comparatively, 0.3% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Solventum has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.
Solventum has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500.
Summary
LivaNova beats Solventum on 9 of the 17 factors compared between the two stocks.
Get LivaNova News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIVN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LIVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LivaNova Competitors List
Related Companies and Tools
This page (NASDAQ:LIVN) was last updated on 9/16/2025 by MarketBeat.com Staff
Free LIVN Stock Alerts